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Inhibitors of Amylases
In this issue of Chemistry & Biology, a library screen-
ing approach reveals a linear octapeptide inhibitor of
a-amylases reached by de novo design [1]. The se-
lected molecule shares characteristics with naturally
occurring protein inhibitors—a result that suggests
general rules for the design of peptide-based amylase
inhibitors may be achievable.
Amylase proteins, part of the broader class of hydrolytic
enzymes called glycosidases, cleave the glycosidic link-
ages of starch into disaccharide fragments that are sub-
sequently broken down into glucose (Figure 1). Inhibi-
tors of amylases have already demonstrated their
utility in aiding diabetics [2]. The glucose levels of dia-
betics can be controlled after meals by administration
of an amylase inhibitor such as acarbose. Acarbose is
a natural product obtained by fermentation and is struc-
turally related to the amylase oligosaccharide substrate,
as up to five glucose residues are known to be accom-
modated in the amylase active site [3].
Interestingly, some plants and microorganisms pro-
duce amylase inhibitors that are based on protein rather
than carbohydrate motifs. These inhibitory proteins,
which range in size from 32 amino acids with 3 disulfide
bonds to over 19 kDa, serve to regulate endogenous
amylase activity, for example in plant seeds, as well as
to defend against digestive amylases from other organ-
isms such as insects [4].
Although X-ray structures for five of the seven protein-
aceous inhibitor family members are known [5–9], the
complex nature of the interaction has made rational de-
sign of smaller versions of these inhibitors challenging.
Phage display methods have been used to produce al-
tered proteins to serve as amylase inhibitors [10, 11].
However, in the last decade, the use of peptides rather
than whole proteins to mimic carbohydrates has
emerged as a strategy for vaccine design as well as for
the design of glycosidase inhibitors [12]. Although meta-bolic stability is an issue, smaller peptides usually are
easier to synthesize than carbohydrates and less likely
to be immunogenic than large proteins. Smaller peptides
are also more amenable to computational modeling to
correlate properties such as charge distribution with ac-
tivity [13]. The 74 amino acid protein Tendamistat has
only 15 amino acids that actually interact with amylase
and therefore has served as a good model for the rational
design of a variety of linear and cyclic peptide inhibitors
[13–16]. However, the discovery of unrelated peptides
has been a challenge. Unrelated peptides have the po-
tential for improved properties such as solubility, stabil-
ity, and selectivity.
In this issue of Chemistry & Biology, the Mares group
reports the generation of a random combinatorial pep-
tide library for the discovery of an octapeptide inhibitor
of the reaction catalyzed by porcine pancreatica-amylase
[1]. Structure/function relationship studies of the result-
ing octapeptide found that addition of a tosylate group
by chemical means to one arginine residue generated
an even tighter binding inhibitor (Figure 1). The new pep-
tide inhibits the porcine a-amylase more strongly than
the clinical drug acarbose. Interestingly, the modified
octapeptide appears to use some of the same binding
motifs as the natural protein-based inhibitors, namely
aromatic and arginine moieties, but arranges these
motifs in a simple linear scaffold. In fact, the flexibility
of the linear scaffold is crucial for effective binding, as
the cyclic version of the same peptide is completely
inactive [1].
Selectivity among varies glycosidase families [17] is
the next issue that has to be addressed in the dis-
covery of inhibitors. Although other a-amylases and
a-glucosidases are also inhibited by the octapeptide,
the new compound does appear to be selective for gly-
cosidases found in family 13. No evidence for inhibition
of enzymes from seven other families was seen. There-
fore, the octapeptide likely will inhibit amylases without
fear of also shutting down other structurally unrelated
glycosidases with important cellular functions.
The work by Mares and coworkers is an important first
step in the de novo design of amylase inhibitors, but
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Inhibitors of the Reaction Catalyzed by Amy-
lase to Break Down Starchmany questions remain. Screening against a wider panel
of glycosidases as they become available will clarify the
extent of the family-selectivity of this new octapeptide.
Structural data characterizing binding of the octapep-
tide to a-amylase is also needed to visualize the features
important for binding and selectivity to serve as a plat-
form for rational design.
In addition, the application of this selection approach
to other glycosidases and carbohydrate binding pro-
teins with and without natural proteinaceous inhibitors
is important to establish if new binding determinants
can be derived using a combinatorial approach. Be-
cause the same structural determinants for amylase in-
hibition emerged from a de novo design approach as
are found for larger proteinaceous inhibitors, general
rules for the design of peptides that mimic natural
carbohydrates may actually be a possibility.
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